CCR3
Assets acting on this target.
- Class
- chemokine receptor antagonist
Assets acting on this target.
2 of 2 assets (2 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| GW766944 | GlaxoSmithKline | CCR3 | Asthma | Ph 2 | EfficacyGW766944, an oral CCR3 antagonist for asthma, failed to significantly reduce sputum or blood eosinophils in a randomized placebo-controlled asthma trial despite achieving high receptor occupancy, and shows no meaningful clinical benefit. Public drug databases list its GSK development status as discontinued. | source ↗ |
| Lazucirnon | Grifols | CCR3 | Age-Related Macular Degeneration | Ph 2 | StrategicAKST4290 (lazucirnon), a CCR3-inhibitor oral small molecule now owned by Grifols via its Alkahest subsidiary, showed positive Phase 2a results in wet AMD and began a Phase 2b trial (PHTHALO-205), but that trial completed years ago with no announced Phase 3 or regulatory next step. Grifols' current public pipeline and R&D communications discuss the same molecule almost exclusively for Parkinson's disease, not AMD. | source ↗ |